Enovid, an innovative anti-viral spray developed in Canada by an Israeli researcher and manufactured in Israel, has been proven effective in preventing viruses – including COVID-19 – from entering the body through the nasal cavity. Read more...
Read MoreHorizons and Jerusalem-based OurCrowd lead US$24 million Series B funding round Funding will go towards the expansion of a third-phase clinical trial of a nasal spray aimed at treating and preventing Covid-19 Read more...
Read MoreVANCOUVER, British Columbia–(BUSINESS WIRE)–SaNOtize Research & Development Corp., (“SaNOtize”), a Canadian anti-infective-focused therapeutics company, today announced an oversubscribed $24 million Series B funding to advance its nitric oxide-based therapeutics pipeline. The lead treatment in the pipeline is the company’s nitric oxide nasal spray (NONS™), shown in clinical studies to treat and prevent COVID-19 infection, including a recent Phase 3 study published in The Lancet Regional Health Southeast Asia. The new funding round was co-led by Horizons Ventures and OurCrowd, with participation from ABC International, and enables SaNOtize to expand its research program, including its ongoing global Phase 3 NONS prevention clinical study with plans to recruit up to 3,000 participants in Canada and Sri Lanka. Read more...
Read MoreThere are currently zero authorized or approved preventative COVID therapies in the U.S. but Canadian biotech SaNOtize wants to change that, charting plans to move a nasal spray into a phase 3 study as soon as October. Read more...
Read MoreNew Delhi: Using Nitric Oxide Nasal Spray (NONS) six times a day for seven days can accelerate the removal of SARS-CoV-2 from your nasal cavity, preventing the transmission of the virus while also protecting high-risk patients from severe disease, according to data from clinical trials published Tuesday in the journal The Lancet Regional Health Southeast Asia. Read more...
Read More
